Flex Pharma

Flex Pharma names William McVicar President and CEO

Tuesday, August 1, 2017

Flex Pharma, a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with severe neurological diseases including multiple sclerosis (MS), Charcot-Marie-Tooth (CMT) and amyotrophic lateral sclerosis (ALS) under FDA Fast Track designation, announced that the Board of Directors has appointed William McVicar, Ph.D., as President and Chief Executive Officer of Flex Pharma.

[Read More]